Abstract
Purpose of Review
The purposes of this study were to describe how medication prices are established, to explain why antihyperglycemic medications have become so expensive, to show trends in expenditures for antihyperglycemic medications, and to highlight strategies to control expenditures in the USA.
Recent Findings
In the U.S., pharmaceutical manufacturers set the prices for new products. Between 2002 and 2012, expenditures for antihyperglycemic medications increased from $10 billion to $22 billion. This increase was primarily driven by expenditures for insulin which increased sixfold. The increase in insulin expenditures may be attributed to several factors: the shift from inexpensive beef and pork insulins to more expensive genetically engineered human insulins and insulin analogs, dramatic price increases for the available insulins, physician prescribing practices, policies that limit payers’ abilities to negotiate prices, and nontransparent negotiation of rebates and discounts.
Summary
The costs of antihyperglycemic medications, especially insulin, have become a barrier to diabetes treatment. While clinical interventions to shift physician prescribing practices towards lower cost drugs may provide some relief, we will ultimately need policy interventions such as more stringent requirements for patent exclusivity, greater transparency in medication pricing, greater opportunities for price negotiation, and outcomes-based pricing models to control the costs of antihyperglycemic medications.
This is a preview of subscription content, access via your institution.
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
White JR Jr. A brief history of the development of diabetes medications. Diabetes Spectr. 2014;27:82–6.
•• Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316:858–71. This article reviews the origins and effects of high drug prices in the U.S. and discusses policy options that might control their cost.
The RED BOOK Online Search-Micromedex Solutions; Micromedex 2.0, (electronic version). Truven Health Analytics, Greenwood Village. Available at: http://www.micromedexsolutions.com.proxy.lib.umich.edu/ (cited: 08 May 2017).
Greene JA, Riggs KR. Why is there no generic insulin? Historical origins of a modern problem. N Engl J Med. 2015;372:1171–5.
Shayman JA. The design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity? Trans Am Clin Climatol Assoc. 2013;124:46–60.
McEwen LN, Herman WH. Health care utilization and costs of diabetes. Chapter #40 in Diabetes in America, 3rd ed. Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE, Eds. Bethesda, National Institutes of Health, NIH Pub No. 17–1468, 2017.
• Hua X, Carvalho N, Tew M, Huang ES, Herman WH, Clarke P. Expenditures and prices of antihyperglycemic medications in the United States: 2002-2013. JAMA. 2016;315:1400–2. This study reports trends in expenditures for different classes of antihyperglycemic medications in the U.S. that simultaneously consider changes in use and price.
• Carter AW, Heinemann L. If PBMs guard access to drugs, then quis custodiet ipsos custodies? (who will guard the guardians?). J Diabetes Sci Technol. 2016;10:1406–10. This commentary discusses the complex and seemingly obscure factors that drive insulin prices and discusses who benefits from higher drug prices.
Thomas K. Drug makers accused of fixing prices on insulin. The New York Times. 2017. Available at: https://www.nytimes.com/2017/01/30/health/drugmakers-lawsuit-insulin-drugs.html?_r=0. Accessed 9 Feb 2017.
American Diabetes Association. Pharmacologic approaches to glycemic treatment. Sec. 8. In Standards of Medical Care in Diabetes-2017. Diabetes Care. 2017;40(Suppl. 1):S64–74.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–65. Erratum in: Lancet 1998;352:1558.
Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA. 2016;316:313–24.
Zinman B, Wanner C, Lachin JM, EMPA-REG OUTCOME Investigators, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.
Wanner C, Inzucchi SE, Lachin JM, EMPA-REG OUTCOME Investigators, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–34.
Marso SP, Daniels GH, Brown-Frandsen K, LEADER Steering Committee, LEADER Trial Investigators, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.
Marso SP, Bain SC, Consoli A, SUSTAIN-6 Investigators, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.
•• Nathan DM, Buse JB, Kahn SE, Krause-Steinrauf H, Larkin ME, Staten M, et al., GRADE Study Research Group. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 2013;36:2254–61. GRADE is the first pragmatic, comparative effectiveness trial to compare commonly used glucose-lowering medications combined with metformin in patients with recently diagnosed type 2 diabetes. Its overarching goal is to provide better guidance to health care professionals on the choice of glucose-lowering medications.
DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003;289:2254–64.
Chiang JL, Kirkman MS, Laffel LMB, Peters AL. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014;37:2034–54.
Davidson MB. Insulin analogs—is there a compelling case to use them? No! Diabetes Care. 2014;37:1771–4.
• Blumenthal DM, Goldman DP, Jena AB. Outcomes-based pricing as a tool to ensure access to novel but expensive biopharmaceuticals. Ann Intern Med. 2017;166:219–20. This commentary proposes an outcomes-based drug pricing approach that uses real-world clinical outcomes to determine a drug’s efficacy and fair market price. Manufacturers are paid on the basis of the drug’s actual benefits.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Laura N. McEwen, Sarah Stark Casagrande, and Shihchen Kuo declare that they have no conflicts of interest.
William H. Herman is a consultant for Johnson & Johnson and a member of Data Monitoring Committees for Merck Sharp & Dohme and Lexicon Pharmaceuticals.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Economics and Policy in Diabetes
Rights and permissions
About this article
Cite this article
McEwen, L.N., Casagrande, S.S., Kuo, S. et al. Why Are Diabetes Medications So Expensive and What Can Be Done to Control Their Cost?. Curr Diab Rep 17, 71 (2017). https://doi.org/10.1007/s11892-017-0893-0
Published:
DOI: https://doi.org/10.1007/s11892-017-0893-0